Antiangiogenic strategies in hepatocellular carcinoma: current status.
Hepatocellular carcinoma is a leading cause of cancer death worldwide in both adult and pediatric patients. Despite many options, no ideal treatment exists for this highly malignant tumor, and management strategies have varied accordingly. Angiogenesis, the formation of new blood vessels, is an essential component of hepatocellular carcinoma biology. Innovative approaches such as targeting the nontransformed, less resistant, tumor-supporting endothelial cells are currently under investigation in hepatocellular carcinoma. This review will focus on the current knowledge of the pathophysiology of hepatocellular carcinoma angiogenesis, as well as the reported data with angiogenesis inhibitors against hepatocellular carcinoma.
Zacharoulis
Dimitris
D
Department of Surgery, University of Thessally, Larisa, Greece. zachadim@yahoo.com
Hatzitheofilou
Constantine
C
Athanasiou
Evangelos
E
Zacharoulis
Stergios
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic
D020533:Angiogenesis Inhibitors